Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Parallel Group Study to Explore the Pharmacokinetics of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors and Normal or Reduced Hepatic Function According to the Child-Pugh System

NCT00706095 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00706095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00706095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Parallel Group Study to Explore the Pharmacokinetics of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors and Normal or Reduced Hepatic Function According to the Child-Pugh System
Lead sponsor
Eisai Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 29, 2008
Completion date
April 30, 2010
Enrollment
18 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cancer